Projects

View
Name PRISM2
Long Name Psychiatric Ratings using Intermediate Stratified Markers 2
Description Currently, neurological disorders are diagnosed primarily on the basis of patients’ symptoms, and not on the causes of the disease. Furthermore, many symptoms appear in a number of diseases, yet we don’t always know if the causes of a given symptom are the same across diseases or not. Pinpointing the underlying causes of symptoms and diseases is essential if we are to develop targeted treatments for these complex conditions. IMI’s PRISM project focused on social withdrawal, a common early symptom of many neurological disorders. The “Big Idea” behind the PRISM project is that a quantitative biological approach to the understanding of neuropsychiatric disorders offers major advantages over the principally symptomatic and convention-based approach to diagnostic categorization used at present. PRISM shed new light on the underlying causes of social withdrawal in schizophrenia and Alzheimer’s disease, including some of the genes involved as well as a neural network. Interestingly, the neural network involved in social withdrawal appears to be the same in both diseases. The team also developed an early version of a suite of tests, including scans, blood tests and smartphone monitoring, which could potentially make it easier to diagnose conditions, indicate the brain mechanisms involved, and identify targets for new treatments. The goal of the PRISM 2 project is to build on the achievements of the original PRISM project. Specifically, it aims to validate PRISM’s findings on social withdrawal in schizophrenia and Alzheimer’s disease, and investigate whether they also apply to major depressive disorder. Ultimately, the work of PRISM 2 should ensure that these findings will result in more accurate diagnoses and treatments for people with Alzheimer’s disease, schizophrenia and major depressive disorder.
Objectives The overall aim of the PRISM project is to develop a quantitative, transdiagnostic neurobiological approach to the understanding of neuropsychiatric disorders in order to accelerate the discovery and development of better treatments. Objective 1: To determine the reproducibility of the transdiagnostic and pathophysiological relationship between DMN integrity and social dysfunction in SZ and AD and its potential to generalise to Major Depressive Disorders (MDD). Objective 2: To test the causality between the quantitative variation in DMN integrity and social dysfunction. Objective 3: To translate and communicate the project results for the benefit of stakeholders including patients and their families, regulators, health care providers, the general public, learned societies, and the pharmaceutical industry, amongst others.
Website https://prism2-project.eu
Start date 01-06-2021
End date 31-05-2024
Logo
Name Projects Type of institution Country  
Stichting Katholieke Universiteit / Radboud University Nijmegen Medical Centre EPAD EQIPD PRISM AMYPAD PD-MitoQUANT PRISM2 Academia Netherlands
VU University Medical Center Amsterdam EPAD AMYPAD IM2PACT PRISM MOPEAD RADAR-CNS RADAR-AD EMIF PRISM2 Pharma-Cog EPND Academia Netherlands
Boehringer Ingelheim International Gmbh PRISM EPAD EQIPD AETIONOMY EMIF Pharma-Cog PRISM2 EFPIA Germany
Academisch Ziekenhuis Leiden PRISM IM2PACT ROADMAP IDEA-FAST PRISM2 Academia Netherlands
Alma Mater Studiorum - Universita Di Bologna PRISM Mobilise-D PRISM2 Academia Italy
Consorcio Centro De Investigacion Biomedica En Red M.P. PRISM RADAR-CNS PRISM2 Academia Spain
Rijksuniversiteit Groningen PRISM EQIPD ROADMAP PRISM2 Academia Netherlands
Stichting Buro Ecnp PRISM EQIPD PRISM2 Academia Netherlands
Biotrial PRISM PRISM2 SME France
Concentris Research Management GmbH PRISM EQIPD EMIF PRISM2 SME Germany
P1vital Limited PRISM PRISM2 SME United Kingdom
Sbgneuro LTD PRISM PRISM2 SME United Kingdom
Psychogenics Inc EQIPD PRISM2 EFPIA United States
Cohen Veterans Bioscience Inc, Cambridge PRISM2 Other United States
WP number Description Project  
WP1 Project Management and Governance PRISM2
WP2 Data management, sustainability, and analysis PRISM2
WP3 Clinical study implementation and operations PRISM2
WP4 Preclinical back-translation and biological validation PRISM2
WP5 Ethics and engagement with regulatory groups, agencies and other stakeholders PRISM2
WP6 Dissemination, communication, exploitation and training PRISM2
Deliverable number Title Project Submission date Link Keywords  
D6.1 Dissemination and Communication Plan PRISM2 31-08-2021 https://prism2-project.eu/wp-content/uploads/2021/09/D6.1-deliverable_report_communication_plan.pdf
D6.2 Go-live of updated public project website PRISM2 30-09-2021 https://prism2-project.eu/wp-content/uploads/2021/09/Deliverable-report-D6.2.pdf
Title First author last name Year Project Link Keywords  
No entries in table
Title Description Type Project  
No entries in table

 

Back to list